Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

This review analyzes the LIDA trial findings, demonstrating that an abbreviated 3-month romosozumab course followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing costs and treatment burden.
Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes

Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes

This review synthesizes the landmark RADIANT trial findings, demonstrating the efficacy of transitioning patients from multiple daily injections to tubeless automated insulin delivery, while integrating broader evidence on genetic susceptibility and metabolic comorbidity management.
Differential Pathophysiological Roles of Centrum Semiovale Perivascular Spaces in Cerebral Amyloid Angiopathy and Deep Perforator Arteriopathy: A Biomarker Synthesis

Differential Pathophysiological Roles of Centrum Semiovale Perivascular Spaces in Cerebral Amyloid Angiopathy and Deep Perforator Arteriopathy: A Biomarker Synthesis

This review synthesizes evidence distinguishing perivascular space enlargement mechanisms in cerebral amyloid angiopathy (CAA) versus deep perforator arteriopathy (DPA), highlighting the diagnostic utility of CSF Aβ42/40 ratios in vascular amyloid pathology.